Validation of distant metastases risk-groups in oral cavity squamous cell carcinoma patients treated with postoperative intensity-modulated radiotherapy.
Radiother Oncol. 2019 May;134:10-16
An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).
J Immunother Cancer. 2019 Mar 13;7(1):72
Oncologist. 2019 Mar 04;:
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
Cancer. 2019 Apr 15;125(8):1341-1349
Metal ion trend in patients with metal-on-metal total hip arthroplasty: a 10-year prospective study.
Hip Int. 2018 Nov;28(2_suppl):43-47
Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
Cancer Immunol Immunother. 2019 May;68(5):773-785
Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520.
Target Oncol. 2019 Feb;14(1):67-74
Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library.
Oncologist. 2019 Apr;24(4):e146-e148
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.
Eur J Cancer. 2019 Jan;107:1-7
Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma.
Ann Oncol. 2019 Jan 01;30(1):57-67